Quantcast
Channel: News – Aspireo Pharmaceuticals Ltd.
Browsing latest articles
Browse All 14 View Live

Somatoprim is a potent agonist of Somatostatin Receptors 2 and 5

Tel Aviv, 26 June 2012. Aspireo Pharmaceuticals Limited, a biopharmaceutical company focused on the development of a novel somatostatin analog, announced today that the research group of Prof. Schulz...

View Article



Evotec and Aspireo enter into strategic advisory agreement

Teaming up to partner Aspireo’s Somatoprim (DG3173) Hamburg, Germany & Tel Aviv, Israel – 28 September 2012: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) and Aspireo Pharmaceuticals Limited...

View Article

Aspireo starts Somatoprim Phase IIa Study in Acromegaly Patients

First Patient Dosed in First Proof-Of-Concept Study in Untreated Acromegaly Patients Tel Aviv, Israel – 6th November 2012: Aspireo Pharmaceuticals Limited, (“Aspireo”) an Israeli biopharmaceutical...

View Article

Aspireo Receives Positive Opinion from EMA for Orphan Disease Designation for...

Somatoprim Recommended For Designation as Orphan Medicinal Product for Acromegaly Tel Aviv, Israel – 26th November 2012: Aspireo Pharmaceuticals Limited, (“Aspireo”) an Israeli biopharmaceutical...

View Article

Aspireo Reports Phase I b Interim Data for Somatoprim

Preliminary Data Analysis Supports Excellent Safety and Side Effect Profile of Somatoprim Tel Aviv, Israel – 7th January 2013: Aspireo Pharmaceuticals Limited, (“Aspireo”) an Israeli biopharmaceutical...

View Article


Aspireo Reports Somatoprim Phase IIa Proof of Concept Results in Acromegaly

Somatoprim reduces human growth hormone secretion safely and effectively in acromegaly patients Tel Aviv, Israel, 3rd April 2013: Aspireo Pharmaceuticals Limited (“Aspireo”), an Israeli...

View Article

Aspireo Reports Start of Further Phase I Study in Healthy Volunteers

First subjects treated with Somatoprim or comparator in cross-over design Tel Aviv, Israel, 18th June 2013: Aspireo Pharmaceuticals Limited (“Aspireo”), an Israeli biopharmaceutical company, focused on...

View Article

FDA Grants Orphan Drug Designation for Aspireo’s Somatoprim

Tel Aviv, Israel – 25 September 2013: Aspireo Pharmaceuticals Limited, (“Aspireo”) an Israeli biopharmaceutical company, focused on the development of Somatoprim, a novel somatostatin analog (SSA),...

View Article


Aspireo Reports Data in Further Phase Ib Study

Somatoprim Demonstrates Superior Side Effect Profile Over Octreotide Tel Aviv, Israel, 22 April 2014: Aspireo Pharmaceuticals Limited (“Aspireo”), an Israeli biopharmaceutical company, focused on the...

View Article


Aspireo’s Somatoprim (DG3173) Program Acquired by Cortendo for USD $30 Million

Sole Aspireo Investor, TVM Capital, to Participate in Cortendo Financing Tel Aviv, Israel, 18 May 2015: Aspireo Pharmaceuticals Limited (“Aspireo”), an Israeli biopharmaceutical company, focused on the...

View Article
Browsing latest articles
Browse All 14 View Live




Latest Images